Home Business & Economics

Business & Economics

Loretta Itri, M.D., Joins Immunomedics as Chief Medical Officer

Biotech company Immunomedics today confirmed the appointment of Loretta Itri, M.D. as Chief Medical Officer (CMO). In her new...

OSE Immunotherapeutics and MAbSilico to Use AI in ADC Development

OSE Immunotherapeutics,  a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology...

LakePharma and NJ Bio to Provide Streamlined Antibody-Drug Conjugate Services

Defying the traditional division between Contract Research Organizations (CRO) and contract development and manufacturing (CDMO), LakePharma has become the...

Syndivia In-Licenses SATT Conectus’ DARx Technology

France-based research-driven biotechnology company Syndivia receives the exclusive license from SATT Conectus to DARx technology. The novel technology allows...

European Regulators Approve Polatuzumab Vedotin, Triggering Milestone Payment for Seattle Genetics

The European Commission's conditional marketing authorization of polatuzumab vedotin (Polivy®; Genentech/Roche) earlier this week triggered a milestone payment which...

Belantamab Mafodotin Receives Priority Review for Relapsed or Refractory Multiple Myeloma

The United States Food and Drug Administration (FDA) has granted a priority review of a Biologics License Application (BLA)...

Boehringer Ingelheim Venture Fund and PPF Group Close a US $ 22M Series C...

Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round...

James Panek Joins Sutro Biopharma’s Board of Directors

James P. Panek, an independent consultant since 2011, providing technical and strategic insights to companies around the world, has...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement

Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology...

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca)*, a HER2 directed...